ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help

|
|
|
|

Trending News

Mitochondria-Booster NIAGEN® Shows Promise in First Human Clinical Trial

Exploring the association between Morgellons disease and Lyme disease: identification of Borrelia bu...

New Envita Study Shows Chronic Lyme Disease "Fools" Immune System, Resistant to Antibiotics

Safely Burn Away Body Fat

Omega-3 fatty acids boost B vitamin brain benefit

Substantial health threat: Never-before-seen tick-borne disease

Trigger identified that likely unleashes autoimmune disease

Lyme Advocates Call on IDSA to Focus on Patient Care Instead of Attacking Those in Distress

Zinc deficiency linked to chronic inflammation

New records of the Lyme disease bacterium in ticks collected from songbirds in central and eastern C...

 
Print Page
Email Article

Long-Term Effects of Savella for Fibromyalgia Evaluated

  [ 6 votes ]   [ Discuss This Article ]
www.ProHealth.com • March 4, 2013


Article:

A 3-Year, Open-Label, Flexible-Dosing Study of Milnacipran for the Treatment of Fibromyalgia.
– Source: The Clinical Journal of Pain, February 26, 2013

By L.M. Arnold, R.H. Palmer and Y. Ma

Abstract:

OBJECTIVES: To evaluate the effects of long-term milnacipran [brand name Savella] treatment in fibromyalgia patients.

METHODS:
Patients completing a previous milnacipran study were eligible to participate in this long-term (up to 3.25 y), open-label study. After washout, dose escalation, and 8 weeks of stable-dose treatment (100 mg/d), patients received flexible doses of milnacipran (50 to 200 mg/d) for the remainder of the study.

Safety evaluations included adverse events and vital signs. Clinical measures included weekly recall pain [visual analog scale (VAS)], Patient Global Disease Status (PGDS), and the Short Form-36 Health Survey [SF-36, including the Physical Component Summary (PCS) and Mental Component Summary scores]. Cohort analyses were conducted to assess the effects of milnacipran over varying periods of time.

RESULTS: Of 1227 patients entering the study, 585 (47.7%) were classified as completers, including 379 (30.9%) patients who were currently enrolled when the study was administratively terminated. Mean duration of treatment was 19 months, with 206 patients reaching the final visit and receiving 36 to 38 months of study treatment.

  • The percentage of patients with ?1 treatment-emergent adverse event was 88.3%, with nausea (25.9%) and headache (13.4%) being the most common events.

  • Discontinuations due to adverse events occurred in 20.9% of patients.

  • Potentially clinically significant increases in blood pressure or heart rate occurred in ?1.1% of patients.

  • Mean improvement from baseline in weekly recall VAS pain was 17.6; improvements in global status (PGDS) and physical functioning (SF-36 PCS) were also observed.

  • In all patient cohorts, these improvements were observed by month 3 and remained relatively constant over time.

  • At final study visit in the 3-year cohort, 70.3% of patients rated their overall fibromyalgia as "much improved" or "very much improved."

DISCUSSION: No new safety concerns were identified in this long-term study. Sustained symptom improvements were found in fibromyalgia patients who received up to 3.25 years of milnacipran treatment.


Source: The Clinical Journal of Pain, February 26, 2013. By L.M. Arnols, R.H. Palmer and Y. Ma. Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati, Cincinnati, OH; Forest Research Institute Inc., Jersey City, NJ.




Please Discuss This Article:   Post a Comment 



[ Be the first to comment on this article ]




 
Free Chronic Fatigue Syndrome and Fibromyalgia Newsletters
Subscribe to
Our FREE
Newsletter
Subscribe Now!
Receive up-to-date ME/CFS & Fibromyalgia treatment and research news
 Privacy Guaranteed  |  View Archives

Save on Nutritional Supplement Orders

Featured Products

Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
FibroSleep™ by ProHealth FibroSleep™ by ProHealth
The All-in-One Natural Sleep Aid
Vitamin D3 Extreme™ by ProHealth Vitamin D3 Extreme™ by ProHealth
50,000 IU Vitamin D3 - Prescription Strength

Natural Remedies

Magnesium + Malic Acid: One-Two Punch for Pain & Fatigue Magnesium + Malic Acid: One-Two Punch for Pain & Fatigue
Irritable Bowel Syndrome: Unlocking the Secrets of Peppermint, Acacia and Fennel Irritable Bowel Syndrome: Unlocking the Secrets of Peppermint, Acacia and Fennel
Three-Step Strategy to Reverse Mitochondrial Aging Three-Step Strategy to Reverse Mitochondrial Aging
Breaking Through the Mental Fog Breaking Through the Mental Fog
Research Links Green Tea to Weight Loss Research Links Green Tea to Weight Loss

FIBROMYALGIA RESOURCES
What is Fibromyalgia?
Fibromyalgia Diagnosis
Fibromyalgia Symptoms
Fibromyalgia Treatments
| CFS RESOURCES
What is CFS?
ME/CFS Diagnosis
ME/CFS Symptoms
ME/CFS Treatments
| FORUMS
Fibromyalgia
ME/CFS
ADVANCED MEDICAL LABS
WHOLESALE  |  AFFILIATES
GUARANTEE  |  PRIVACY
CONTACT US
LIBRARY
RSS
SITE MAP
ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus
Credit Card Processing